Immediate Impact
1 from Science/Nature 56 standout
Citing Papers
Neoadjuvant Chemoimmunotherapy for NSCLC
2024 Standout
Non-small-cell lung cancer
2024 Standout
Works of Mark D. Sborov being referenced
E1505: Adjuvant chemotherapy +/- bevacizumab for early stage NSCLC—Outcomes based on chemotherapy subsets.
2016
Author Peers
| Author | Last Decade | Papers | Cites | ||||
|---|---|---|---|---|---|---|---|
| Mark D. Sborov | 179 | 159 | 49 | 83 | 8 | 244 | |
| Fisher Ri | 113 | 109 | 29 | 42 | 11 | 247 | |
| Ronald Boonstra | 187 | 216 | 14 | 135 | 10 | 298 | |
| Sabine Oeschger | 68 | 139 | 25 | 64 | 9 | 241 | |
| Mohammed Al‐Hamadani | 164 | 173 | 22 | 75 | 10 | 292 | |
| Frank Kauff | 170 | 231 | 29 | 154 | 8 | 259 | |
| Alice E. Schluger | 114 | 177 | 34 | 65 | 8 | 291 | |
| Alessandra Dondi | 165 | 199 | 16 | 73 | 14 | 247 | |
| Emanuela Anna Pesce | 164 | 250 | 29 | 64 | 11 | 279 | |
| T Anderson | 156 | 123 | 29 | 59 | 8 | 242 | |
| Viola Pöschel | 180 | 227 | 30 | 72 | 8 | 284 |
All Works
Loading papers...